About Us
Engineering Therapeutics to Treat Diseases Resulting from Abelson Tyrosine Kinase Dysfunction
ABLi Therapeutics takes aim at neurodegenerative disease by targeting the non-receptor Abelson Tyrosine Kinases (Abl kinases or c-Abl) with small molecule inhibitors to intervene where disease begins.
Our proprietary Re-engineering Approach with Metabolism Preserved (RAMP™) drug innovation engine utilizes clinically validated data of kinase inhibitors to design and develop novel product candidates with enhanced penetration into the brain, with potentially higher potency and improved safety to treat diseases in which kinase activation is implicated.
Our Focus
Impacting Patient Lives by Treating Disease Where it Begins
We are engineering Abl kinase inhibitors to treat Parkinson’s disease, Parkinson’s-related neurodegenerative diseases and other neurological diseases associated with Abl kinase dysfunction inside and outside of the brain. These protein kinases have been shown to play a critical role in monitoring insults to brain neurons and regulating biological pathways that are associated with neurodegeneration. Recent research has demonstrated that Abl kinases play a central role in Parkinson’s disease initiation and progression.
Watch to learn more about our disease modifying strategy for Parkinson’s disease.
Risvodetinib
Breaking the Cycle of Neurodegeneration and Neuroinflammation in Parkinson’s Disease
Learn MorePipeline
Our RAMP™ drug innovation engine facilitates the development of more selective Abl inhibitors with greater potency and safety than commercially marketed Abl kinase inhibitors used as anti-cancer agents. The c-Abl inhibitors that have emerged from our development can be administered chronically and systemically.
Learn MoreContact Us
For more information regarding our company, partnerships, or drug candidate(s), please reach out to us info@ablitherapeutics.com.
Investor Relations
Mike Moyer, Life Science Advisors, mmoyer@lifesciadvisors.com, +1-617-308-4306